BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Dr. Reddy’s Laboratories Q2 FY26 Results Preview: Revenue Seen at ₹8,710 Cr, PAT at ₹1,400 Cr

Dr. Reddy’s Laboratories Q2 FY26 Results Preview: Revenue Seen at ₹8,710 Cr, PAT at ₹1,400 Cr

Synopsis:


Dr. Reddy’s Laboratories is expected to post revenue of ₹8,710 crore in Q2 FY26, up 8.6% YoY. EBITDA is estimated at ₹2,160 crore, down 5.4% YoY, while PAT is projected at ₹1,400 crore, marking an 11.3% YoY increase and a 1.4% QoQ decline.


Source:
Bloomberg Estimates

Dr. Reddy’s Laboratories Ltd. is expected to announce its Q2 FY26 results on October 24, 2025, followed by an analyst concall later in the evening. The company’s quarterly performance is likely to show moderate revenue growth, steady profitability, and some margin compression.

Revenue for the quarter is estimated at ₹8,710 crore, reflecting an increase compared with the same quarter last year and a marginal rise over the previous quarter. Operating profit (EBITDA) is expected at ₹2,160 crore, which would be lower than both the previous year and the earlier quarter.

EBITDA margins are projected at 24.8%, narrowing from the levels seen a year ago and slightly lower than the last quarter. Net profit (PAT) is expected to be ₹1,400 crore, showing an improvement from last year and a small dip compared with the preceding quarter.

DR. REDDY S LABORATORIES

Trade

1279.4-9.29 (-0.72 %)

Updated - 23 October 2025
1303.60day high
DAY HIGH
1271.60day low
DAY LOW
1991213
VOLUME (BSE)

Dr. Reddy’s Laboratories Q2FY26 Preview

Particulars

Q2 FY26E

Q2 FY25

YoY

Q1 FY26

QoQ

Revenue (₹ bn)

87.1

80.2

8.6%

85.5

1.9%

EBITDA (₹ bn)

21.6

22.8

-5.4%

22.2

-3.0%

EBITDA Margin (%)

24.8%

28.4%

-367 bps

26.0%

-124 bps

PAT (₹ bn)

14.0

12.6

11.3%

14.2

-1.4%

Overall Outlook

For Q2 FY26, Dr. Reddy’s estimates point to an increase in revenue and profit compared with the same period last year, while EBITDA margins are expected to narrow both annually and QoQ.

The detailed performance update, quarter-to-quarter analysis, and potential dividend update will be shared post the company’s result announcement on October 24, 2025.

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|